User:HlynurT/Discovery and development of thalidomide and its analogs
From Wikipedia, the free encyclopedia
Introduction
Thalidomide | |
---|---|
Drug class | |
Class identifiers | |
ATC code | L04AX |
Biological target | Immunosuppressant |
Legal status |
This user page or section is in a state of significant expansion or restructuring. You are welcome to assist in its construction by editing it as well. If this user page has not been edited in several days, please remove this template. If you are the editor who added this template and you are actively editing, please be sure to replace this template with {{in use}} during the active editing session. Click on the link for template parameters to use.
This page was last edited by CommonsDelinker (talk | contribs) 6 months ago. (Update timer) |
Thalidomide once marketed as a antiemetic and sedative drug in the late 1950s was banned in 1961 after it‘s teratogenic properties were observed. However thalidomide was later found out to be both antiangiogenetic and anti-inflammatory yielding a new way of fighting number of immunological and inflammatory diseases. Recently, thalidomide has been approved by the Food and Drug Administration (FDA) for use in newly diagnosed multiple myeloma (MM) under strict regulations.[1] Thalidomides teratogenic properties led to the development of analogs with fewer side effects and increased potency which include lenalidomide which is marketed, pomalidomide which has an orphan drug status and apremilast which is in clinical phase, all of which are manufactured by Celgene.